Johnson & Johnson reported positive results from the first clinical study of its OTTAVA Robotic Surgical System for gastric bypass procedures. Goldman Sachs added JNJ to its U.S. May Directors Cut Conviction List, citing it as a top defensive growth stock. The company is also highlighted as a low-risk buy for 2026, with diversified pharma and MedTech growth outperforming peers like Pfizer.